GlaxoSmithKline’s CEO Emma Walmsley Tries to Conquer Old R&D Demons

Published: Aug 07, 2017

Close to a decade ago, GSK CEO Andrew Witty and R&D chief Moncef Slaoui decided they needed to do something new and different to fire up a lackluster R&D group, looking to shock a system where researchers were far too focused on hanging on to unpromising drugs.

Now, new CEO Emma Walmsley says she has inherited the exact same problem they vowed to fix.

Back to news